- $0.11m
- -$5.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.02 | ||
| Price to Tang. Book | 0.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -403.5% | ||
| Return on Equity | -204.6% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Directors
- Andrew Kay NEC
- Hugh Griffith CEO (53)
- Donald Munoz CFO (52)
- Adam George NID (51)
- James Healy NID (56)
- Cyrille Leperlier NID (67)
- Martin Mellish NID (63)
- Bali Muralidhar NID (41)
- Rafaele Tordjman NID (51)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 28th, 1997
- Public Since
- September 28th, 2017
- No. of Employees
- 20
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 142,037,000
- Address
- Lochside House, 3 Lochside Way, EDINBURGH, EH12 9DT
- Web
- https://www.nucana.com/
- Phone
- +44 1312483660
- Contact
- Christopher Brinzey
- Auditors
- Ernst & Young LLP
Upcoming Events for NCNA
Similar to NCNA
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the NuCana share price?
As of Today at 22:22 UTC, shares in NuCana are trading at $3.73. This share price information is delayed by 15 minutes.
How has the NuCana share price performed this year?
Shares in NuCana last closed at $3.73 and the price had moved by -99.43% over the past 365 days. In terms of relative price strength the NuCana share price has underperformed the S&P500 Index by -99.51% over the past year.
What are the analyst and broker recommendations for NuCana?
The overall consensus recommendation for NuCana is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the NuCana dividend yield?
NuCana does not currently pay a dividend.
Does NuCana pay a dividend?
NuCana does not currently pay a dividend.
When does NuCana next pay dividends?
NuCana does not currently pay a dividend.
How do I buy NuCana shares?
To buy shares in NuCana you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NuCana?
As of the previous close price of $3.73, shares in NuCana had a market capitalisation of $0.11m.
Where are NuCana shares listed?
Here are the trading details for NuCana:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NCNA
What kind of share is NuCana?
Based on an overall assessment of its quality, value and momentum NuCana is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NuCana share price forecast for 2025?
The analyst consensus target price for shares in NuCana is $26.29. That is 604.89% above the last closing price of $3.73.
Analysts covering NuCana currently have a consensus Earnings Per Share (EPS) forecast of -£13.00 for the next financial year.
Find out moreWhat is the trend in the NuCana share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NuCana. Over the past six months, its share price has underperformed the S&P500 Index by -98.05%.
As of the last closing price of $3.73, shares in NuCana were trading -97.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NuCana PE Ratio?
The NuCana PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NuCana?
NuCana's management team is headed by:
- Andrew Kay - NEC
- Hugh Griffith - CEO
- Donald Munoz - CFO
- Adam George - NID
- James Healy - NID
- Cyrille Leperlier - NID
- Martin Mellish - NID
- Bali Muralidhar - NID
- Rafaele Tordjman - NID